VistaGen Therapeutics, Inc.
VTGN · NASDAQ
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Market Cap | $76,780 | $104,514 | $25,052 | $245,493 |
| - Cash | $67,131 | $119,166 | $16,638 | $68,135 |
| + Debt | $1,509 | $2,120 | $2,129,911 | $3,039 |
| Enterprise Value | $11,158 | -$12,532 | $2,138,325 | $180,397 |
| Revenue | $486 | $1,064 | -$227 | $1,109 |
| % Growth | -54.3% | 568.7% | -120.5% | – |
| Gross Profit | $486 | $1,064 | -$227 | $1,109 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$55,338 | -$32,453 | -$58,736 | -$47,048 |
| % Margin | -11,386.4% | -3,050.1% | 25,874.9% | -4,242.8% |
| Net Income | -$51,418 | -$29,362 | -$59,248 | -$47,762 |
| % Margin | -10,579.8% | -2,759.6% | 26,100.4% | -4,307.2% |
| EPS Diluted | -1.67 | -1.52 | -8.51 | -7.38 |
| % Growth | -9.9% | 82.1% | -15.3% | – |
| Operating Cash Flow | -$42,097 | -$25,813 | -$49,716 | -$45,257 |
| Capital Expenditures | -$191 | -$61 | -$212 | -$200 |
| Free Cash Flow | -$42,288 | -$25,874 | -$49,928 | -$45,457 |